Savara (SVRA) Shares Outstanding (2010 - 2026)
Savara's (SVRA) quarterly Shares Outstanding (Entity) came in at $216.4 million in Q2 2025, up 18.54% year-on-year from $182.6 million in Q2 2024, and little changed on a QoQ basis from $216.1 million in Q1 2025.
Savara (SVRA) Shares Outstanding (2010 - 2026) Analysis & Trends
Savara (SVRA) has 12 years of Shares Outstanding (Entity) data on file, last reported at $216.4 million in Q2 2025.
- On a quarterly basis, Shares Outstanding (Entity) rose 18.54% year-over-year to $216.4 million in Q2 2025; TTM through Jun 2025 was $216.4 million, a 18.54% increase from a year earlier, with the FY2024 full-year figure at $172.4 million, up 24.81% from the prior year.
- Shares Outstanding (Entity) for Q2 2025 stood at $216.4 million, roughly flat from $216.1 million in the prior quarter.
- Over the last five years, Shares Outstanding (Entity) for SVRA reached as high as $216.4 million in Q2 2025 and fell as low as $77.0 million in Q1 2021.
- Historically, Shares Outstanding (Entity) has averaged $157.1 million across 5 years, with a median of $152.8 million in 2022.
- Across the five-year window, Shares Outstanding (Entity) surged 188.62% in 2021 and dropped 11.41% in 2023, its largest moves.
- Year by year, Shares Outstanding (Entity) stood at $114.0 million in 2021, then jumped by 33.97% to $152.8 million in 2022, then decreased by 9.58% to $138.1 million in 2023, then rose by 24.81% to $172.4 million in 2024, then climbed by 25.52% to $216.4 million in 2025.
- Per Business Quant data, the three most recent Shares Outstanding (Entity) figures were $216.4 million in Q2 2025, $216.1 million in Q1 2025, and $172.4 million in Q4 2024.
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Shares Outstanding (Qtr) |
|---|---|---|---|---|---|
| 1 | Oculis Holding AG | 68,785.72 Bn | 68,785.72 Bn | - | 6,012.74 Bn |
| 2 | Nanobiotix | 1,895.57 Bn | 1,895.51 Bn | - | 47.82 Bn |
| 3 | BeOne Medicines | 471.35 Bn | 466.56 Bn | 1.35 Bn | 1.44 Bn |
| 4 | NuCana | 279.75 Bn | 279.75 Bn | - | 11.23 Bn |
| 5 | Vertex Pharmaceuticals | 120.24 Bn | 113.00 Bn | 2.59 Bn | 254.10 Mn |
| 6 | Regeneron Pharmaceuticals | 67.80 Bn | 59.04 Bn | 3.31 Bn | 104.00 Mn |
| 7 | Belite Bio | 62.51 Bn | 62.51 Bn | - | 400.00 Mn |
| 8 | Argenx Se | 57.38 Bn | 57.38 Bn | 1.41 Bn | 62.19 Mn |
| 9 | Revolution Medicines | 37.78 Bn | 37.78 Bn | - | 198.10 Mn |
| 10 | Savara | 1.24 Bn | 1.24 Bn | - | 253.28 Mn |
Historic Data
Download Data| Date | Value |
|---|---|
| Mar 31, 2026 | 253.28 Mn |
| Dec 31, 2025 | 222.39 Mn |
| Sep 30, 2025 | 216.46 Mn |
| Jun 30, 2025 | 216.43 Mn |
| Mar 31, 2025 | 216.15 Mn |
| Dec 31, 2024 | 198.19 Mn |
| Sep 30, 2024 | 211.85 Mn |
| Jun 30, 2024 | 182.58 Mn |
| Mar 31, 2024 | 182.55 Mn |
| Dec 31, 2023 | 165.20 Mn |
| Sep 30, 2023 | 164.34 Mn |
| Jun 30, 2023 | 152.80 Mn |
| Mar 31, 2023 | 152.78 Mn |
| Dec 31, 2022 | 152.77 Mn |
| Sep 30, 2022 | 152.77 Mn |
| Jun 30, 2022 | 152.77 Mn |
| Mar 31, 2022 | 152.77 Mn |
| Dec 31, 2021 | 133.92 Mn |
| Sep 30, 2021 | 152.59 Mn |
| Jun 30, 2021 | 152.46 Mn |